Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-19T07:58:23.720Z Has data issue: false hasContentIssue false
  • English
  • Français

Diverse Glial Cell Line-Derived Neurotrophic Factor (GDNF) Support Between Mania and Schizophrenia: A Comparative Study in Four Major Psychiatric Disorders

Published online by Cambridge University Press:  15 April 2020

Z. Tunca ,
B. Kıvırcık Akdede ,
A. Özerdem ,
T. Alkın ,
S. Polat ,
D. Ceylan ,
M. Bayın ,
N. Cengizçetin Kocuk ,
S. Şimşek  and
H. Resmi
...Show all authors
Z. Tunca*
Affiliation:
Dokuz Eylul University, Medical School, Izmir, Turkey
B. Kıvırcık Akdede
Affiliation:
Dokuz Eylul University, Medical School, Izmir, Turkey
A. Özerdem
Affiliation:
Dokuz Eylul University, Medical School, Izmir, Turkey
T. Alkın
Affiliation:
Dokuz Eylul University, Medical School, Izmir, Turkey
S. Polat
Affiliation:
Manisa, Turkey
D. Ceylan
Affiliation:
Gümüşhane, Turkey
M. Bayın
Affiliation:
Niğde, Turkey
N. Cengizçetin Kocuk
Affiliation:
Bingöl, Turkey
S. Şimşek
Affiliation:
Hatay, Turkey
H. Resmi
Affiliation:
Dokuz Eylul University, Medical School, Izmir, Turkey
P. Akan
Affiliation:
Dokuz Eylul University, Medical School, Izmir, Turkey
*
*Corresponding author at: Dokuz Eylul University, Medical School, Department of Psychiatry, Balcova, 35340 Izmir, Turkey. Tel.: +90 232 412 41 50. E-mail addresses:zeliha.tunca@deu.edu.tr, tunca@superonline.com (Z. Tunca).
Get access

Abstract

Background:

Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) have essential roles in synaptic plasticity which is involved in pathogenesis and treatment of psychiatric disorders. However, it is not clear whether they act simultaneously during illness states in major psychiatric disorders.

Methods:

BDNF and GDNF serum levels were measured concomitantly by enzyme-linked immunosorbent assay (ELISA) method in 171 patients diagnosed with schizophrenia (n = 33), bipolar disorder-manic episode (n = 39), bipolar/unipolar depression (n = 64, 24/40) and obsessive-compulsive disorder (n = 35) according to DSM-IV, and 78 healthy volunteers. SCID-I and SCID non-patient version were used for clinical evaluation of the patients and healthy volunteers, respectively. Correlations between the two trophic factor levels, and illness severity scores, duration of illness and medication dosages were studied across different illnesses.

Results:

While patients had equally lower BDNF levels in all diagnoses, GDNF levels were significantly higher in mania and lower in schizophrenia compared to healthy controls. BDNF levels were negatively correlated to illness severity scores in affective episodes (mania and depression). Longer duration of illness (> 5 years) had an impact on lower GDNF levels in schizophrenia. BDNF levels and antipsychotic drug dosages in schizophrenia, and GDNF levels and antidepressant drug dosages in obsessive-compulsive disorder were positively correlated.

Conclusion:

Our data confirmed the evidence of equally deficient neuronal support by BDNF in all major psychiatric illnesses, but suggested a diverse glial functioning between schizophrenia and mania.

Keywords

Brain-derived neurotrophic factor (BDNF)Glial cell line-derived neurotrophic factor (GDNF)SchizophreniaManiaDepressionObsessive-compulsive disorder
Type
Original article
Information
European Psychiatry , Volume 30 , Issue 2 , February 2015 , pp. 198 - 204
Copyright
Copyright © Elsevier Masson SAS 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Retired in September 16, 2014.

2

Formerly, residents in Dokuz Eylul University, Medical School, Department of Psychiatry.

References

Airaksinen, M.S., Saarma, M.. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3 :383–394.CrossRefGoogle ScholarPubMed
Allen, N.J., Barres, B.. Signaling between glia and neurons: focus on synaptic plasticity. Curr Opin Neurobiol 2005;5 :542–548.CrossRefGoogle Scholar
Angelucci, F., Brenè, S., Mathé, A.A.. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005;10 :345–352.CrossRefGoogle ScholarPubMed
Autry, A.E., Monteggia, L.M.. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012;64 :238–258.CrossRefGoogle ScholarPubMed
Bai, O., Chlan-Fourney, J., Bowen, R., Keegan, D., Li, X.M.. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71 :127–131.CrossRefGoogle ScholarPubMed
Balaratnasingam, S., Janca, A.. Brain-derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther 2012;134 :116–124.CrossRefGoogle ScholarPubMed
Barbosa, I.G., Huguet, R.B., Sousa, L.P., Abreu, M.N.S., Rocha, N.P., Bauer, M.E., et al.Circulating levels of GDNF in bipolar disorder. Neurosci Lett 2011;502 :103–106.CrossRefGoogle ScholarPubMed
Bezzi, P., Volterra, A.. A neuron-glia signalling network in the active brain. Curr Opin Neurobiol 2001;11 :387–394.CrossRefGoogle ScholarPubMed
Bocchio-Chiavetto, L., Bagnardi, V., Zanardini, R., Molteni, R., Nielsen, M.G., Placentino, A., et al.Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010;11 :763–773.CrossRefGoogle ScholarPubMed
Buckley, P.F., Pillai, A., Howell, K.R.. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011;24 :122–127.CrossRefGoogle Scholar
Busner, J., Targum, S.D.. The Clinical Global Impressions Scale applying a research tool in clinical practice. Psychiatry 2007;4 :28–37.Google ScholarPubMed
Cotter, D.R., Pariante, C.M., Everall, I.P.. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001;55 :585–595.CrossRefGoogle ScholarPubMed
Diniz, B.S., Teixeira, A.L., Miranda, A.S., Talib, L.L., Gattaz, W.F., Forlenza, O.V.. Circulating Glial-derived neurotrophic factor is reduced in late-life depression. J Psychiat Res 2012;46 :135–139.CrossRefGoogle ScholarPubMed
dos Santos, I.M., Ciulla, L., Braga, D., Ceresér, K.M., Gama, C.S., Kapczinski, F., et al.Symptom dimensional approach and BDNF in unmedicated obsessive-compulsive patients: an exploratory study. CNS Spectr 2011;16 :179–189.CrossRefGoogle Scholar
Duman, R.S., Malberg, J., Nakagawa, S., D'sa, C.. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000;48 :732–739.CrossRefGoogle ScholarPubMed
Durany, N., Michel, T., Zöchling, R., Boissl, K.W., Cruz-Sánchez, F.F., Riederer, P., et al.Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001;52 :79–86.CrossRefGoogle ScholarPubMed
Encinas, M., Tansey, MG, Tsui-Pierchala, B.A., et al.c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci 2001;21 :1464–1472.CrossRefGoogle Scholar
Favalli, G., Li, J., Belmonte-de-Abreu, P., Wong, A.H.C., Daskalakis, Z.J.. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res 2012;46 :1–11.CrossRefGoogle ScholarPubMed
Fernandes, B.S., Berk, M., Turck, C.W., Steiner, J., Gonçalves, C.. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 2014;19 :750–751.CrossRefGoogle ScholarPubMed
Fernandes, B.S., Gama, C.S., Ceresér, K.M., Yatham, L.N., Fries, G.R., Colpo, G., et al.Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011;45 :995–1004.CrossRefGoogle ScholarPubMed
First, M.B., Spitzer, R.L., Gibbon, M.Structured clinical ınterview for DSM-IV-TR Axis I Disorders, research version. New York: Biometrics Research, New York State Psychiatric Institute; 2002.Google Scholar
Fontenelle, L.F., Barbosa, I.G., Victor Luna, J., Pessoa Rocha, N., Silva Miranda, A., Teixeira, A.L.Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res 2012;199 :195–200.CrossRefGoogle ScholarPubMed
Frye, M.A., Watzl, J., Banakar, S., O’Neill, J., Mintz, J., Davanzo, P., et al.Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 2007;32 :2490–2499.CrossRefGoogle ScholarPubMed
Gama, C.S., Andreazza, A.C., Kunz, M., Berk, M., Belmonte-de-Abreu, P.S., Kapczinski, F.Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007;420 :45–48.CrossRefGoogle ScholarPubMed
Gardner, D.M., Murphy, A.L., O’Donnell, H., Centorrino, F., Baldessarini, R.J.International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167 :686–693.CrossRefGoogle ScholarPubMed
González-Pinto, A., Mosquera, F., Palomino, A., Alberich, S., Gonza, A., Ortiz, A.Increase in brain-derived neurotrophic factor in first-episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol 2010;25 :241–245.CrossRefGoogle ScholarPubMed
Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleischmann, R.L., Hill, C.L., et al.The Yale-Brown Obsessive-compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46 :1006–1011.CrossRefGoogle ScholarPubMed
Gould, T.D., Zarate, C.A., Manji, H.K.Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004;65 :10–21.CrossRefGoogle ScholarPubMed
Granholm, C., Reyland, M., Albeck, D., Sanders, L., Gerhardt, G., Hoernig, G., et al.Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J Neurosci 2000;20 :3182–3190.CrossRefGoogle ScholarPubMed
Green, M.J., Matheson, S.L., Shepherd, A., Weickert, C.S., Carr, V.J.Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011;16 :960–972.CrossRefGoogle ScholarPubMed
Hamilton, M.A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23 :56–62.CrossRefGoogle ScholarPubMed
Hansen, R.A., Moore, C.G., Dusetzina, S.B., Leinwand, B.I., Gartlehner, G., Gaynes, B.N.Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Med Decis Making 2009;29 :91–103.CrossRefGoogle ScholarPubMed
Hisaoka, K., Nishida, A., Koda, T., Miyata, M., Zensho, H., Morinobu, S., et al.Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 2001;79 :25–34.CrossRefGoogle ScholarPubMed
Hisaoka, K., Takebayashi, M., Tsuchioka, M., Maeda, N., Nakata, Y.Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 2007;321 :148–157.CrossRefGoogle ScholarPubMed
Hunsberger, J., Austin, D.R., Henter, I.D.The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 2009;11 :333–348.Google ScholarPubMed
Jindal, R.D., Pillai, A.K., Mahadik, S.P., Eklund, K., Montrose, D.M., Keshavan, M.S.Decreased BDNF in patients with antipsychotic naïve first-episode schizophrenia. Schizophr Res 2010;119 :47–51.CrossRefGoogle ScholarPubMed
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J.M.Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002;109 :143–148.CrossRefGoogle ScholarPubMed
Kay, S.R., Fiszbein, A., Opler, L.A.The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13 :261–276.CrossRefGoogle Scholar
Kondziella, D., Brenner, E., Eyjolfsson, E.M., Sonnewald, U.How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem Int 2007;50 :291–301.CrossRefGoogle ScholarPubMed
Lee, K., Kunugi, H., Nanko, S.Glial cell line-derived neurotrophic factor (GDNF) gene and schizophrenia: polymorphism screening and association analysis. Psychiatry Res 2001;104 :11–17.CrossRefGoogle ScholarPubMed
Lee, B.H., Kim, Y.K.Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiol 2009;59 :51–58.CrossRefGoogle Scholar
Lin, P.Y.State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009;466 :139–143.CrossRefGoogle ScholarPubMed
Lin, L.F., Doherty, D.H., Lile, J.D., Bektesh, S., Collins, F.GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;21 :1130–1132.CrossRefGoogle Scholar
Liu, Q., Zhu, H.Y., Li, B., Wang, Y.Q., Yu, J., Wu, G.C.Chronic clomipramine treatment restores hippocampal expression of glial cell line-derived neurotrophic factor in a rat model of depression. J Affect Disord 2012;141 :367–372.CrossRefGoogle Scholar
Maina, G., Rosso, G., Zanardini, R., Bogetto, F., Gennarelli, M., Bocchio-Chiavetto, L.Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: a case-control study. J Affect Disord 2010;122 :174–178.CrossRefGoogle ScholarPubMed
Marsman, A., van den Heuvel, M.P., Klomp, D.W., Kahn, R.S., Luijten, P.R., Hulshoff Pol, H.E.Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull 2013;39 :120–129.CrossRefGoogle Scholar
Michel, T.M., Frangou, S., Camara, S., Thiemeyer, D., Jecel, J., Tatschner, T., et al.Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative postmortem study. Eur Psychiatry 2008;23 :413–420.CrossRefGoogle Scholar
Michelato, A., Bonvicini, C., Ventriglia, M., Scassellati, C., Randazzo, R., Bignotti, S., et al.3′ UTR(AGG)n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. Neurosci Lett 2004;357 (3):235237.CrossRefGoogle Scholar
Mizuno, T., Omata, N., Murata, T., Mitsuya, H., Maruoka, N., Mita, K., et al.Mania: not the opposite of depression, but an extension? Neuronal plasticity and polarity. Med Hypotheses 2013;81 :175–179.CrossRefGoogle ScholarPubMed
Niitsu, T., Shirayama, Y., Matsuzawa, D., Shimizu, E., Hashimoto, K., Iyo, M.Association between serum levels of glial cell line-derived neurotrophic factor and attention deficits in schizophrenia. Neurosci Lett 2014;575 :37–41.CrossRefGoogle Scholar
Ohrmann, P., Siegmund, A., Suslow, T., Spitzberg, K., Kersting, A., Arolt, V., et al.Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2005;73 :153–157.CrossRefGoogle Scholar
Olbrich, H.M., Valerius, G., Rüsch, N., Buchert, M., Thiel, T., Hennig, J., et al.Frontolimbic glutamate alterations in first-episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 2008;9 :59–63.CrossRefGoogle ScholarPubMed
Ongur, D., Drevets, W.C., Price, J.L.Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998;95 :13290–13295.CrossRefGoogle ScholarPubMed
Ongur, D., Jensen, J.E., Prescot, A.P., Stork, C., Lundy, M., Cohen, B.M., et al.Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 1998;90 :13290–13295.Google Scholar
Otsuki, K., Uchida, S., Watanuki, T., Wakabayashi, Y., Fujimoto, M., Matsubara, T., et al.Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res 2008;42 :1145–1153.CrossRefGoogle ScholarPubMed
Patil, S.T., Zhang, L., Martenyi, F., Lowe, S.L., Jackson, K.A., et al.Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13 :1102–1107.CrossRefGoogle ScholarPubMed
Paz, R.D., Tardito, S., Atzori, M., Tseng, K.Y.Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008;18 :773–786.CrossRefGoogle ScholarPubMed
Pirildar, S., Gönül, A.S., Taneli, F., Akdeniz, F.Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004;28 :709–713.CrossRefGoogle Scholar
Pittenger, C., Krystal, J.H., Coric, V.Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006;3 :69–81.CrossRefGoogle ScholarPubMed
Rajkowska, G.Dysfunction in neural circuits involved postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000;48 :766–777.CrossRefGoogle Scholar
Rizos, E.N., Papathanasiou, M., Michalopoulou, P.G., Mazioti, A., Douzenis, A., Kastania, A., et al.Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophr Res 2011;129 :201–204.CrossRefGoogle ScholarPubMed
Rorick-Kehn, L.M., Johnson, B.G., Knitowski, K.M., Salhoff, C.R., Witkin, J.M., Perry, K.W., et al.In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007;193 :121–136.CrossRefGoogle ScholarPubMed
Rosa, A.R., Frey, B.N., Andreazza, A.C., Ceresér, K.M., Cunha, A.B.M., Quevedo, J., et al.Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett 2006;407 :146–150.CrossRefGoogle ScholarPubMed
Saavedra, A., Baltazar, G., Santos, P., Carvalho, C.M., Duarte, E.P.Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol Dis 2006;23 :533–542.CrossRefGoogle ScholarPubMed
Shao, Z., Dyck, L.E., Wang, H., Li, X.M.Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells. J Psychiatry Neurosci 2006;31 :32–37.Google ScholarPubMed
Sharma, H.S.Post-traumatic application of brain-derived neurotrophic factor and glia-derived neurotrophic factor on the rat spinal cord enhances neuroprotection and improves motor function. Acta Neurochir 2006;96 (Suppl).329334.CrossRefGoogle ScholarPubMed
Takebayashi, M., Hisaoka, K., Nishida, A., Tsuchioka, M., Miyoshi, I., Kozuru, T., et al.Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 2005;9 :1–6.Google ScholarPubMed
Théberge, J., Williamson, K.E., Aoyama, N., Drost, D.J., Manchanda, R., Malla, A.K., et al.Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007;191 :325–334.CrossRefGoogle ScholarPubMed
Toyooka, K., Asama, K., Watanabe, Y., Muratake, T., Takahashi, M., Someya, T.Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002;110 :249–257.CrossRefGoogle ScholarPubMed
Tunca, Z., Ozerdem, A., Ceylan, D., Yalçın, Y., Can, G., Resmi, H., et al.Alterations in BDNF (brain-derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: the role of lithium. J Affect Disord 2014;166 :193–200.CrossRefGoogle ScholarPubMed
Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A.A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133 :429–435.CrossRefGoogle ScholarPubMed
Yoshimura, R., Hori, H., Ikenouchi-sugita, A., Umene-nakano, W., Katsuki, A.Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol 2012;27 :33–38.CrossRefGoogle ScholarPubMed
Wang, Y., Mathews, C.A., Li, Y., Lin, Z., Xiao, Z.Brain-derived neurotrophic factor (BDNF) plasma levels in drug-naïve OCD patients are lower than those in healthy people, but are not lower than those in drug-treated OCD patients. J Affect Disord 2011;133 :305–310.CrossRefGoogle Scholar
Weickert, C.S., Hyde, T.M., Lipska, B.K., Herman, M.M., Weinberger, D.R., Kleinman, J.E.Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003;8 :592–610.CrossRefGoogle ScholarPubMed
Williams, H.J., Norton, N., Peirce, T., Dwyer, S., Williams, N.M., Moskvina, V., et al.Association analysis of the glial cell line-derived neurotrophic factor (GDNF) gene in schizophrenia. Schizophr Res 2007;97 :271–276.CrossRefGoogle Scholar
Xiu, M.H., Hui, L., Dang, Y.F., Hou, T.D., Zhang, C.X., Zheng, Y.L.Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009;33 :1508–1512.CrossRefGoogle ScholarPubMed
Vostrikov, V.M., Uranova, N.A., Orlovskaya, D.D.Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007;94 :273–280.CrossRefGoogle ScholarPubMed
Zagrebelsky, M., Korte, M.Neuropharmacology form follows function: BDNF and its involvement in sculpting the function and structure of synapses. Neuropharmacol 2014;76 :628–638.CrossRefGoogle ScholarPubMed
Zarate, C., Du, J., Quiroz, J., Gray, N., Denicoff, K., Singh, J., et al.Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann NY Acad Sci 2003;1003 :273–291.CrossRefGoogle ScholarPubMed
Zhang, X., Zhang, Z., Xie, C., Xi, G., Zhou, H., Zhang, Y., et al.Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32 :886–890.CrossRefGoogle ScholarPubMed
Zurn, D., Winkel, L., Menoud, A., Djabali, K., Aebischer, P.Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro. J Neurosci Res 1996;44 :133–141.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.